Lacidipine and blood pressure variability in diabetic hypertensive patients

Alessandra Frattola, Gianfranco Parati, Paolo Castiglioni, Felice Paleari, Luisa Ulian, Giovanni Rovaris, Gabriele Mauri, Marco Di Rienzo, Giuseppe Mancia

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The aim of our study was to assess the effects of lacidipine, a long-acting calcium antagonist, on 24-hour average blood pressure, blood pressure variability, and baroreflex sensitivity. In 10 mildly to moderately hypertensive patients with type II diabetes mellitus (aged 18 to 65 years), 24-hour ambulatory blood pressure was continuously monitored noninvasively (Portapres device) after a 3-week pretreatment with placebo and a subsequent 4-week once daily lacidipine (4 mg) or placebo treatment (double-blind crossover design). Systolic blood pressure, diastolic blood pressure, and heart rate means were computed each hour for 24 hours (day and night) at the end of each treatment period. Similar assessments were also made for blood pressure and heart rate variability (standard deviation and variation coefficient) and for 24-hour baroreflex sensitivity, which was quantified (1) in the time domain by the slope of the spontaneous sequences characterized by progressive increases or reductions of systolic blood pressure and RR interval and (2) in the frequency domain by the squared ratio of RR interval and systolic blood pressure spectral power ≃0.1 and 0.3 Hz over the 24 hours. Compared with placebo, lacidipine reduced the 24-hour, daytime, and nighttime systolic and diastolic blood pressure (P

Original languageEnglish
Pages (from-to)622-628
Number of pages7
JournalHypertension
Volume36
Issue number4
Publication statusPublished - 2000

Fingerprint

Blood Pressure
Baroreflex
Placebos
lacidipine
Heart Rate
Cross-Over Studies
Type 2 Diabetes Mellitus
Calcium
Equipment and Supplies
Therapeutics

Keywords

  • Baroreflex
  • Blood pressure monitoring, ambulatory
  • Calcium antagonists
  • Diabetes mellitus
  • Hypertension, essential

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Frattola, A., Parati, G., Castiglioni, P., Paleari, F., Ulian, L., Rovaris, G., ... Mancia, G. (2000). Lacidipine and blood pressure variability in diabetic hypertensive patients. Hypertension, 36(4), 622-628.

Lacidipine and blood pressure variability in diabetic hypertensive patients. / Frattola, Alessandra; Parati, Gianfranco; Castiglioni, Paolo; Paleari, Felice; Ulian, Luisa; Rovaris, Giovanni; Mauri, Gabriele; Di Rienzo, Marco; Mancia, Giuseppe.

In: Hypertension, Vol. 36, No. 4, 2000, p. 622-628.

Research output: Contribution to journalArticle

Frattola, A, Parati, G, Castiglioni, P, Paleari, F, Ulian, L, Rovaris, G, Mauri, G, Di Rienzo, M & Mancia, G 2000, 'Lacidipine and blood pressure variability in diabetic hypertensive patients', Hypertension, vol. 36, no. 4, pp. 622-628.
Frattola, Alessandra ; Parati, Gianfranco ; Castiglioni, Paolo ; Paleari, Felice ; Ulian, Luisa ; Rovaris, Giovanni ; Mauri, Gabriele ; Di Rienzo, Marco ; Mancia, Giuseppe. / Lacidipine and blood pressure variability in diabetic hypertensive patients. In: Hypertension. 2000 ; Vol. 36, No. 4. pp. 622-628.
@article{ba5c24a7be6b4ba58132cffd9a3d7547,
title = "Lacidipine and blood pressure variability in diabetic hypertensive patients",
abstract = "The aim of our study was to assess the effects of lacidipine, a long-acting calcium antagonist, on 24-hour average blood pressure, blood pressure variability, and baroreflex sensitivity. In 10 mildly to moderately hypertensive patients with type II diabetes mellitus (aged 18 to 65 years), 24-hour ambulatory blood pressure was continuously monitored noninvasively (Portapres device) after a 3-week pretreatment with placebo and a subsequent 4-week once daily lacidipine (4 mg) or placebo treatment (double-blind crossover design). Systolic blood pressure, diastolic blood pressure, and heart rate means were computed each hour for 24 hours (day and night) at the end of each treatment period. Similar assessments were also made for blood pressure and heart rate variability (standard deviation and variation coefficient) and for 24-hour baroreflex sensitivity, which was quantified (1) in the time domain by the slope of the spontaneous sequences characterized by progressive increases or reductions of systolic blood pressure and RR interval and (2) in the frequency domain by the squared ratio of RR interval and systolic blood pressure spectral power ≃0.1 and 0.3 Hz over the 24 hours. Compared with placebo, lacidipine reduced the 24-hour, daytime, and nighttime systolic and diastolic blood pressure (P",
keywords = "Baroreflex, Blood pressure monitoring, ambulatory, Calcium antagonists, Diabetes mellitus, Hypertension, essential",
author = "Alessandra Frattola and Gianfranco Parati and Paolo Castiglioni and Felice Paleari and Luisa Ulian and Giovanni Rovaris and Gabriele Mauri and {Di Rienzo}, Marco and Giuseppe Mancia",
year = "2000",
language = "English",
volume = "36",
pages = "622--628",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Lacidipine and blood pressure variability in diabetic hypertensive patients

AU - Frattola, Alessandra

AU - Parati, Gianfranco

AU - Castiglioni, Paolo

AU - Paleari, Felice

AU - Ulian, Luisa

AU - Rovaris, Giovanni

AU - Mauri, Gabriele

AU - Di Rienzo, Marco

AU - Mancia, Giuseppe

PY - 2000

Y1 - 2000

N2 - The aim of our study was to assess the effects of lacidipine, a long-acting calcium antagonist, on 24-hour average blood pressure, blood pressure variability, and baroreflex sensitivity. In 10 mildly to moderately hypertensive patients with type II diabetes mellitus (aged 18 to 65 years), 24-hour ambulatory blood pressure was continuously monitored noninvasively (Portapres device) after a 3-week pretreatment with placebo and a subsequent 4-week once daily lacidipine (4 mg) or placebo treatment (double-blind crossover design). Systolic blood pressure, diastolic blood pressure, and heart rate means were computed each hour for 24 hours (day and night) at the end of each treatment period. Similar assessments were also made for blood pressure and heart rate variability (standard deviation and variation coefficient) and for 24-hour baroreflex sensitivity, which was quantified (1) in the time domain by the slope of the spontaneous sequences characterized by progressive increases or reductions of systolic blood pressure and RR interval and (2) in the frequency domain by the squared ratio of RR interval and systolic blood pressure spectral power ≃0.1 and 0.3 Hz over the 24 hours. Compared with placebo, lacidipine reduced the 24-hour, daytime, and nighttime systolic and diastolic blood pressure (P

AB - The aim of our study was to assess the effects of lacidipine, a long-acting calcium antagonist, on 24-hour average blood pressure, blood pressure variability, and baroreflex sensitivity. In 10 mildly to moderately hypertensive patients with type II diabetes mellitus (aged 18 to 65 years), 24-hour ambulatory blood pressure was continuously monitored noninvasively (Portapres device) after a 3-week pretreatment with placebo and a subsequent 4-week once daily lacidipine (4 mg) or placebo treatment (double-blind crossover design). Systolic blood pressure, diastolic blood pressure, and heart rate means were computed each hour for 24 hours (day and night) at the end of each treatment period. Similar assessments were also made for blood pressure and heart rate variability (standard deviation and variation coefficient) and for 24-hour baroreflex sensitivity, which was quantified (1) in the time domain by the slope of the spontaneous sequences characterized by progressive increases or reductions of systolic blood pressure and RR interval and (2) in the frequency domain by the squared ratio of RR interval and systolic blood pressure spectral power ≃0.1 and 0.3 Hz over the 24 hours. Compared with placebo, lacidipine reduced the 24-hour, daytime, and nighttime systolic and diastolic blood pressure (P

KW - Baroreflex

KW - Blood pressure monitoring, ambulatory

KW - Calcium antagonists

KW - Diabetes mellitus

KW - Hypertension, essential

UR - http://www.scopus.com/inward/record.url?scp=0033779354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033779354&partnerID=8YFLogxK

M3 - Article

C2 - 11040246

AN - SCOPUS:0033779354

VL - 36

SP - 622

EP - 628

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 4

ER -